• 64Cu-SAR-bisPSMA detected 2.6x more lesions than 68Ga-PSMA-11
• 64Cu-SAR-bisPSMA identified prostate cancer in 78% of patients vs. 36% with 68Ga-PSMA-11
• 64Cu-SAR-bisPSMA changed planned patient management in 44% of cases

Clarity Pharmaceuticals announced the release of an abstract on the Co-PSMA investigator-initiated trial, which evaluated the performance of its 64Cu-SAR-bisPSMA diagnostic in a head-to-head comparison to the standard-of-care 68Ga-PSMA-11 in 50 prostate cancer patients with biochemical recurrence. The study, led by Prof. Louise Emmett at St Vincent's Hospital Sydney, found that 64Cu-SAR-bisPSMA PET/CT identified a statistically significant greater number of prostate cancer lesions per patient than 68Ga-PSMA-11 PET/CT. The mean per-patient lesion count was 1.26 for 64Cu-SAR-bisPSMA compared to 0.48 for 68Ga-PSMA-11, a 2.63-fold difference. In total, 64Cu-SAR-bisPSMA next-day imaging detected 63 lesions compared to only 24 lesions with 68Ga-PSMA-11. At the patient level, 64Cu-SAR-bisPSMA identified prostate cancer in 78% of cases, compared to only 36% with 68Ga-PSMA-11. Importantly, the planned patient management changed in 44% of cases following the 64Cu-SAR-bisPSMA PET/CT assessment. These results further build on previous data showing the superior performance of 64Cu-SAR-bisPSMA over standard PSMA PET agents, enabling more effective and targeted treatment of prostate cancer.

Clarity believes 64Cu-SAR-bisPSMA has the potential to become the new standard-of-care in PSMA PET imaging and significantly grow the market opportunity by substantially improving the diagnosis of prostate cancer across various stages of the disease.